CEBP Meeting Calendar Targets
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sweeney, C.
Right arrow Articles by Vaughan, T. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sweeney, C.
Right arrow Articles by Vaughan, T. L.
Cancer Epidemiology Biomarkers & Prevention Vol. 12, 527-533, June 2003
© 2003 American Association for Cancer Research

Glutathione S-transferase M1, T1, and P1 Polymorphisms and Survival among Lung Cancer Patients1

Carol Sweeney2, Valle Nazar-Stewart, Patricia L. Stapleton, David L. Eaton and Thomas L. Vaughan

Division of Epidemiology, University of Minnesota, Minneapolis, Minnesota 55454 [C. S.]; Center for Research on Environmental and Occupational Toxicology, Oregon Health and Science University, Portland, Oregon [V. N-S.]; Departments of Environmental Health [P. L. S., D. L. E.] and Epidemiology [T. L. V.], University of Washington, Seattle, Washington; and Program in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, Washington [T. L. V.]


   Abstract
Top
 Abstract
Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Glutathione S-transferase (GST) enzymes detoxify therapeutic drugs and reactive oxidants, so GST polymorphisms may influence survival after diagnosis of cancer. We evaluated survival according to GST polymorphisms in a population-based series of lung cancer patients. The study subjects (n = 274) were men diagnosed with lung cancer from 1993 through 1996 who participated in a case control study and provided a blood sample for genotyping. The presence of the GSTM1 and GSTT1 genes were assayed by multiplex PCR. Genotype at the GSTP1 Ile105Val substitution was determined by PCR and oligonucleotide ligation assay. The study subjects were followed for vital status through 2000, and overall survival was evaluated in Kaplan-Meier survival functions and Cox proportional hazards models. Subjects with the GSTM1 null genotype had shorter survival; the proportion of GSTM1 null subjects surviving at 5 years was 0.20 [95% confidence interval (CI) 0.14–0.27], compared with 0.29 (95% CI 0.22–0.37) for GSTM1 present subjects. The relative risk of death associated with GSTM1 null genotype, adjusted for stage at diagnosis and histology, was 1.36, 95% CI 1.04–1.80. There was no association between GSTT1 or GSTP1 genotype and survival in the overall study population, nor in a subgroup of patients treated with chemotherapy (n = 130). For GSTM1, our results are consistent with a previous study, which also observed that the GSTM1-null genotype, which confers susceptibility to lung cancer, was associated with shorter survival. Future studies of lung cancer survival should take into account GSTM1 genotype as well as investigate underlying mechanisms.


   Introduction
Top
 Abstract
 Introduction
Subjects and Methods
 Results
 Discussion
 References
 
Inherited GST3 variants that alter GST-mediated detoxification of carcinogenic chemicals have been extensively investigated as candidate genes for lung cancer susceptibility (1, 2, 3, 4) . GST polymorphisms may also affect cancer survival, but fewer molecular epidemiology investigations to date have considered the role of genetic variation in these enzymes in determining survival. Hypotheses about GST polymorphisms and survival have been developed through two lines of reasoning: (a) several chemotherapy agents are substrates for GST-catalyzed glutathione conjugation (1 , 5, 6, 7, 8, 9) , as are cellular by-products of reactive oxygen damage (10 , 11) ; therefore, patients may differ in response to chemo and radiation therapy depending on GST activity; and (b) susceptible GST genotypes have been reported to be associated with characteristic patterns of somatic changes in tumor tissue (e.g., p53 or K-ras mutations; Refs. 12, 13, 14, 15 ); if patients with low-activity GST genotypes are more likely to have certain somatic changes, and if the somatic changes represent more aggressive tumor phenotypes (16) , GST genotype may be observed to associate with survival differences.

Three studies have reported on survival of lung cancer patients in relation to common polymorphisms affecting GST activity, with inconsistent results. Goto et al. (17) observed a hospital-based series of 232 NSCLC patients for ≤5 years and reported that patients who were homozygous for deletion of the GSTM1 gene (GSTM1-null genotype) had shorter survival than patients with one or two GSTM1 alleles (GSTM1 present genotype, which represents normal GSTM1 activity). In contrast, no association between mean disease-free survival time and GSTM1 genotype was reported in a series of 105 surgically treated NSCLC patients observed for 5 years (18) . In a third study of 250 lung cancer cases (all histologies were included), GSTM1 genotype, the GSTT1 gene deletion, and the GSTP1 Ile105Val single nucleotide polymorphism were studied in relation to survival, and the overall proportion surviving at 1 year was similar across categories of each GST genotype (19) . These investigations differed in several aspects of study design, including size of the study populations, observation of NSCLC patients only or of all lung cancers, length of follow-up, and choice of different end points, death versus disease-free interval. The discordant results may be related to these differences in approach.

Thus, there are plausible mechanisms through which a cancer patient’s inherited genotype for GST enzymes may influence his or her survival, but evidence for a role of these genetic differences in lung cancer survival is limited. Characterization of associations between drug metabolizing enzyme polymorphisms and patient prognosis could contribute to identifying individual differences in potential to benefit from particular types of therapy. We have investigated survival in relation to genotype for three common GST polymorphisms in a population-based cohort of men with lung cancer.


   Subjects and Methods
Top
 Abstract
 Introduction
 Subjects and Methods
Results
 Discussion
 References
 
The study subjects were men aged 18–74 with a first diagnosis of primary lung cancer (all histologies) in 1993 through 1996 in six nonurban counties of western Washington state. Men meeting these eligibility criteria were ascertained through the Western Washington CSS, a population-based SEER program cancer registry (20) . Eligible subjects were contacted and asked to complete a structured telephone interview for a case control study. We requested that subjects who participated in the interview also provide a blood sample for genotyping. The case control study methods and participation rates have been described previously (21) . Although we used a rapid reporting mechanism to identify subjects as quickly as possible after diagnosis, we found that many of the men diagnosed with lung cancer were deceased, too ill to be interviewed, or too ill to provide a blood sample by the time we attempted to contact them for the study. Blood samples were obtained from 42% of the 661 eligible lung cancer case subjects. These 274 patients form the study cohort and were followed for survival for the present analysis.

The age range among the participants was 28–74 years, with a median of 62 years. The majority (263) of the men (96%) were Caucasian, 4 were Native-American, 2 were Asian, 1 was African-American, and race was unknown for 4 men. We obtained information on stage at diagnosis (categorized according to SEER program criteria as local, regional, or distant), tumor site, histology, and type of primary therapy from the CSS. Patients with distant stage of disease at diagnosis were less likely to participate in the blood draw and, therefore, were underrepresented in the group with blood samples (31%) compared with the overall group of eligible lung cancer patients (58%). Participants with blood samples available also differed from eligible patients with no sample with regard to several other characteristics that were correlated with less advanced disease at diagnosis and/or good prognosis, so that lung cancer patients with a blood sample were less likely to be current smokers, were more likely to have a body mass index (calculated as weight in kilograms divided by height in meters, squared) above the median, were more likely to have a tumor location in the upper lobe, and were more likely to have been treated by surgery, compared with all eligible patients.

GST genotypes were determined from DNA extracted from lymphocytes. The presence of GSTM1 and GSTT1 genes was assayed by multiplex PCR (22) , and genotype at the GSTP1 Ile105Val substitution was determined by PCR and the oligonucleotide ligation assay method (23) , with primers and probes for GSTP1 as described previously (24) .

Subjects were followed for vital status through 2000 by the CSS by active follow-up and matching to electronic death certificate records from the state of Washington and the National Center for Health Statistics. Survival analysis methods were used to consider the influence of GST genotypes on patient survival. We calculated survival time as the time from diagnosis to death or to the end of follow-up for each patient. Death from any cause was treated as a failure in the survival analysis, and living subjects were censored at the time of last contact. We calculated person-years at risk within each genotype category as the sum of survival times of all subjects in that category. Overall survival in relation to GST genotype was evaluated by Kaplan-Meier survival function and log-rank tests, stratified by stage at diagnosis. RR of death was estimated by the hazard ratio from a multivariate Cox proportional hazards model, with adjustment for categories of stage at diagnosis as strata in the model and other prognostic characteristics as covariates. RRs within subgroups according to type of therapy, and by tumor histology, were calculated by including a multiplicative interaction term in the Cox model. The likelihood ratio test comparing models with and without the interaction term was used to evaluate the statistical significance of effect modification. Stata software (Stata Corp., College Station, TX) was used for statistical analysis.


   Results
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
Discussion
 References
 
The distributions of GST genotypes according to patient characteristics are shown in Table 1Citation . Genotypes for GSTM1 and GSTT1 were available for all 274 subjects. GSTP1 genotype assay results were not interpretable for 21 subjects, so the GSTP1 analysis is based on 253 subjects. Generally, the distribution of genotypes was not related to stage at diagnosis, tumor histology, or site of the tumor. An association between GSTM1 null genotype and increased risk of lung cancer was present in this study population4 and most apparent for NSCLC; accordingly, the cohort of cases followed for survival contained an excess of GSTM1 null genotypes among subjects with non-small cell type cancers (56%) compared with the total case group (52%). GSTT1 null genotypes were somewhat less frequent (12%) among patients with distant disease at diagnosis than in the overall case group (19%), but this difference was consistent with chance.


View this table:
[in this window]
[in a new window]

  		Table 1 Selected characteristics of 274 men with lung cancer, by GST genotype

 
The Kaplan-Meier survival functions for overall survival among 274 men with lung cancer by GST genotypes are presented in Fig. 1Citation . A total of 214 deaths was observed during the follow-up period. Median follow-up among men who were alive at the end of observation was 77 months from diagnosis. Follow-up was essentially complete to 5 years, with only 1 living subject censored (lost to follow-up) before 4 years and 7 subjects censored between years 4 and 5. On the basis of the difference in the survival curves by GSTM1 genotype shown in Fig. 1Citation A, and on the log-rank test ({chi}2 = 3.36, 1 df, P = 0.07), there was an indication that GSTM1 null individuals had poor survival compared with GSTM1 present subjects. The Kaplan-Meier estimates of overall survival at 1, 3, and 5 years were 0.77 (95% CI 0.69–0.84), 0.39 (96% CI 0.30–0.47), and 0.29 (95% CI 0.22–0.37) for GSTM1 present subjects and 0.77 (95% CI 0.69–0.83), 0.34 (95% CI 0.26–0.41), and 0.2 (95% CI 0.14–0.27) for GSTM1 null subjects. There was no evidence of a survival difference by GSTT1 genotype ({chi}2 = 0.77, 1 df, P = 0.38), nor by GSTP1 genotype ({chi}2 = 0.12, 2 df, P = 0.94).



View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Overall survival among 274 lung cancer patients by GST genotype, Kaplan-Meier function.

 
The RRs of death associated with GSTM1, GSTT1, and GSTP1 genotypes are shown in Table 2Citation . After adjustment for stage and histology, which were strong predictors of survival, GSTM1 null genotype was associated with shorter survival among lung cancer patients, with an adjusted death RR of 1.36, compared with GSTM1 present. Additional adjustment for age, race, education, current smoking, total pack-years of smoking, body mass index, tumor site, or history of a previous primary malignancy had essentially no effect on the RR. The RR of death associated with GSTM1 null genotype among patients with small cell lung cancer (RR = 1.55, 95% CI 0.89–2.7) was similar to that for patients with NSCLC (RR = 1.34, 95% CI 0.94–1.91). For GSTT1 genotype, an adjusted Cox model indicated slightly worse survival associated with the GSTT1-null genotype (RR = 1.17), but this difference is likely to be attributable to chance. RRs for GSTP1 Ile/Val and Val/Val genotypes were very close to the null, indicating no relationship between GSTP1 genotype and survival in this study population.


View this table:
[in this window]
[in a new window]

  		Table 2 GST genotypes and lung cancer survival

 
We were able to determine from registry information whether each patient received radiation and/or chemotherapy. These data were available for 93–95% of genotyped subjects. We examined the association between GST genotype and survival according to type of therapy. The increased hazard of death associated with GSTM1 null genotype appeared to be present among both subjects who received chemotherapy and those who did not (Table 3)Citation . No additional details describing specific chemotherapy drugs were available, so we could not consider possible differences in the role of GSTM1 by the type of chemotherapeutic agent. The GSTM1-survival association was strongest among subjects treated by radiation (Table 4Citation ; RR = 1.86), whereas there was no association between GSTM1 genotype and survival among patients who did not receive radiation (P for interaction = 0.02). Receiving radiation treatment was related to stage at diagnosis; radiation was noted for 69% of patients with regional disease, 64% of those with distant disease and only 12% of patients with local disease. When the patients with local disease who were not routinely treated with radiation therapy were excluded from the Cox proportional hazards model, the interaction between GSTM1 genotype and radiation persisted, and the RRs for GSTM1 by radiation were similar to those shown in Table 4Citation , indicating that the interaction was with radiation and not with stage at diagnosis. Among patients who received both chemotherapy and radiation therapy (n = 97, 84 deaths), the RR associated with GSTM1 null genotype was 1.56 (95% CI 1.01–2.41). Among patients who received neither chemotherapy nor radiation therapy (n = 83, 45 deaths), the RR associated with GSTM1 null genotype was 0.88 (95% CI 0.48–1.6). Consistent with the results from the overall study population, analysis of subgroups by type of therapy did not reveal evidence of associations between GSTT1 or GSTP1 and lung cancer survival.


View this table:
[in this window]
[in a new window]

  		Table 3 GST genotypes and lung cancer survival, by chemotherapy treatment

 

View this table:
[in this window]
[in a new window]

  		Table 4 GST genotypes and lung cancer survival, by radiation treatment

 
Previous studies have assessed GST survival association separately for smokers versus never-smokers. In our study population, only 11 subjects reported being lifetime never-smokers, so an analysis limited to nonsmokers was not possible. When we considered RR of death associated with GSTM1 null genotype by current smoking status, an increased risk for GSTM1 null was seen in both the subjects who were current smokers within a year of diagnosis (n = 155, RR of death associated with GSTM1 null genotype = 1.52, 95% CI 1.06–2.19) and those who were former or never-smokers (n = 119, RR = 1.23, 95% CI 0.80–1.89). Current smokers had slightly poorer survival compared with a reference group that included former smokers and never-smokers (RR = 1.15, 95% CI 0.86–1.53, adjusted for histology and SEER stage). Poor prognosis for smokers was more marked (RR = 1.7, 95% CI 1.14–2.52) in the subgroup of patients who received radiation therapy. Within the subgroups of patients who were treated by chemotherapy or radiation, the influence of GSTM1 genotype on survival did not vary according to smoking status (Ps for interaction 0.68 and 0.97).


   Discussion
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
References
 
In summary, we found that men with lung cancer who had GSTM1 null genotypes had shorter overall survival. When other patient prognostic factors were taken into account in a multivariate model, the GSTM1-survival association remained statistically significant, indicating that the association was independent of stage at diagnosis and histology. GSTM1 null genotype was associated with shorter survival for lung cancer patients with both non-small cell and small cell histologies. However, because of the small number of patients with small cell lung cancer in our study, the CIs were somewhat wide for that group.

The study population that we followed for survival was a population-based sample, and, through the CSS registry, we were able to observe almost all of the participating lung cancer patients from time of diagnosis to ≥5 years or until death. The number of deaths observed during the follow-up period (214) was large enough to provide reasonable power to assess the main effects of the genotypes of interest and rule out any strong associations of GSTT1 or GSTP1 with survival. The GSTM1-survival association was significant; however, the lower 95% confidence limit approached 1. Because the study population was limited to men, and the source population was largely Caucasian, results may not be generalizable to female lung cancer patients or members of other ethnic or racial groups.

The cohort of patients for whom we obtained blood for genotyping represented 42% of the overall eligible population, and participants tended to have lower stage at diagnosis and somewhat better survival than nonparticipants. Poor participation can introduce selection bias in a cohort study when two conditions are met: (a) participation is related to survival; and (b) participation differs according to exposure status, independent of the exposure’s influence on survival. In the present study, participation was related to survival, so one condition that contributes to bias is present. GST genotypes of nonparticipants are not known, so we are unable to evaluate whether these exposures were related to participation. However, GST genotypic variants do not produce any evident phenotype that would be expected to affect an individual’s tendency to participate in a study, so it is unlikely that the second condition was met. Because survival analysis methods rely on comparisons within the cohort of participating patients, differences between participants and nonparticipants should not introduce bias into our estimates of RRs, although generalizability to those who do not survive long after diagnosis may be limited.

Considered in context of previous studies, our result regarding GSTM1 and lung cancer survival is consistent with the GSTM1-survival association described in a study which was similar in design, having a large study population and several years of follow-up. Goto et al. (17) reported that, among 232 NSCLC patients, those with the GSTM1 null genotype had worse survival, with 44% of GSTM1 null patients surviving at 3 years, compared with 55% of patients with GSTM1 present. These results are quite comparable with our study population, in which, when NSCLC cases only were considered, 42% of GSTM1 null versus 48% of GSTM1 present patients survived to 3 years. Yang et al. (19) reported no overall differences in lung cancer survival at 1 year according to GSTM1 genotype. We note that in the present study data, survival at 1 year was essentially identical (77%) in the two GSTM1 genotype categories. It was at 3 and 5 years of follow-up that the increased risk of death among GSTM1-null patients became apparent. Thus, the data presented by Yang et al., after only 1 year of follow-up, are not inconsistent with those of the present study. The third published study of GSTM1 and lung cancer survival that may be compared with the current investigation is the study conducted by Przygodzki et al. (18) . This study found no association between GSTM1 and survival, but because of its smaller study population (n = 105), it would not have had statistical power to detect an association of the magnitude that was observed in our data.

Because GST enzymes are of interest as potential modifiers of the effects of chemotherapy and radiation therapy, we analyzed the associations between all three GST polymorphisms and survival by type of therapy. We found that the GSTM1-survival association was not modified by chemotherapy but appeared to be strongest among patients treated by radiation. The biological significance of this difference according to treatment is unclear. Some limitations of the subgroup analysis by treatment should be acknowledged. Our only source of treatment information was cancer registry data, which may not be completely reliable regarding therapies. Multiple subgroup comparisons according to type of therapy were made, so chance should be considered as an explanation for the interaction between GSTM1 genotype and radiation therapy.

Although the GSTP1 allelic variants have been reported to have different activities in glutathione conjugation of both nitrogen mustard and cisplatin chemotherapy agents in vitro (7 , 8 , 25) , we did not find evidence that GSTP1 genotype influences survival among lung cancer patients, either in the overall study population or a subgroup treated with chemotherapy. GSTT1 genotype was also unrelated to survival. For both GSTP1 and GSTT1, the analysis of subgroups by type of therapy (Tables 3Citation and 4)Citation resulted in some RRs that departed from 1, but these were generally based on small numbers of deaths and not statistically significant. The GSTT1 null or GSTP1 Val/Val genotypes are each present in only ~20% of individuals in the population, so given the size of our study population, we cannot rule out modest associations between GSTT1 and GSTP1 genotypes and survival. The study by Yang et al. (19) presents the only previous data that we are aware of regarding GSTT1 and GSTP1 genotypes in relation to lung cancer survival, and its results also indicated no overall association.

Two possible mechanisms for an association between GSTM1 genotype and survival have been suggested, one involving differences in detoxification of treatment agents or GST-mediated protection against oxidative damage during treatment and the other related to differences in carcinogen damage to DNA. Under the first mechanism, individuals with GSTM1 null genotypes would experience a higher effective dose of chemotherapy and/or more reactive oxidant damage to tumor tissue. Therapy might then be more effective in GSTM1 null patients, in which case we would observe longer survival for this group, as has been reported for GSTM1 null breast cancer patients (26 , 27) . In the present study of lung cancer, the direction of the association was the reverse. Shorter survival for patients with reduced capacity for GST-mediated detoxification might be explained by more severe therapy-related toxicity. An increased number of deaths attributed to therapy-related toxicity was reported among GSTT1 null leukemia patients treated with high-dose therapy (28) . The survival difference that we observed among lung cancer patients was evident ≥3 years after diagnosis and so seems unlikely to be explained by therapy-related toxicity. A possible explanation for the association observed in our data is that GSTM1 null patients may have had dose reductions or delays caused by toxicity and, therefore, received less effective treatment. We have no information on toxicity, dose delays, or reductions in our study population. The shorter survival in association with GSTM1 null genotype that we observed is also in keeping with the model proposed by Goto et al. (17) , in which smokers with GSTM1 null genotype would have more tendency to form carcinogen-DNA adducts in lung tissue and develop cancers that contain mutations of p53, K-ras, and/or genes involved in tumor development, growth, and metastasis. Because of the presence of these mutations, the GSTM1 null patients would be expected to have more aggressive tumor biology and poorer survival, even after taking into account stage, as was observed in the present study.

If GSTM1 genotype affects lung cancer survival, as has now been described in two large study populations, this raises the possibility that survival bias may influence case control studies of GSTM1 genotype in lung cancer etiology. Shorter survival for GSTM1 null patients could result in lower prevalence of the null genotype in the group of cases who are alive and able to participate in a study. If this occurred, the observed odds ratio would be biased low. However, we observed that the proportions of GSTM1 present and GSTM1 null lung cancer patients surviving to 1 year after diagnosis were essentially identical and that survival differences only became apparent after longer follow-up. Therefore, lung cancer case control studies that have ascertained incident cases within a year after diagnosis should not be affected by survival bias. On the basis of our survival data, bias in a study addressing GSTM1 genotype in lung cancer risk would be a concern only if the case group included substantial numbers of prevalent cases.

The evidence of an association between GSTM1 null genotype and increased risk of lung cancer (2, 3, 4) , association of the same genotype with somatic changes in lung tumor tissue (12, 13, 14, 15) , as have been characterized previously, and association between GSTM1 genotype and survival, as described here, presents a complex picture. The implications for patient care, if any, are not clear. The underlying mechanism for the GSTM1-survival association should be further investigated. If the mechanism for the GSTM1-survival association is through the presence of p53 and/or K-ras mutations, as seems plausible, then our results may serve to reinforce the importance of considering GSTM1 genotype in future studies of lung cancer survival.


   Acknowledgments
 
We thank Jason Van Loo for conducting some of the genotyping assays.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by NIH Grants National Cancer Institute (NCI) CA53392, NCI CA62082, and National Institute of Environmental Health Sciences Center Grant ES07033. The Cancer Surveillance System (CSS) is supported by NIH contract N01-PC-67009. Back

2 To whom requests for reprints should be addressed, at Division of Epidemiology, University of Minnesota, 1300 South Second Street #300, Minneapolis, MN 55454. Phone: (612) 626-9096; Fax: (612) 624-0315; E-mail: sweeney{at}epi.umn.edu Back

3 The abbreviations used are: GST, glutathione S-transferase; CSS, Cancer Surveillance System; SEER, Surveillance, Epidemiology, and End Results; df, degrees of freedom; NSCLC, non-small cell lung cancer; RR, relative risk; CI, confidence interval. Back

4 Nazar-Stewart et al., submitted for publication. Back

Received 8/14/02; revised 3/ 4/03; accepted 3/17/03.


   References
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Hayes J. D., Pulford D. J. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol., 30: 445-600, 1995.[Medline]
  2. Houlston R. S. Glutathione S-transferase M1 status and lung cancer risk: a meta-analysis. Cancer Epidemiol. Biomark. Prev., 8: 675-682, 1999.[Abstract/Free Full Text]
  3. McWilliams J. E., Sanderson B. J., Harris E. L., Richert-Boe K. E., Henner W. D. Glutathione S-transferase M1 (GSTM1) deficiency and lung cancer risk. Cancer Epidemiol. Biomark. Prev., 4: 589-594, 1995.[Abstract]
  4. Benhamou S., Lee W. J., Alexandrie A. K., Boffetta P., Bouchardy C., Butkiewicz D., Brockmoller J., Clapper M. L., Daly A., Dolzan V., Ford J., Gaspari L., Haugen A., Hirvonen A., Husgafvel-Pursiainen K., Ingelman-Sundberg M., Kalina I., Kihara M., Kremers P., Le Marchand L., London S. J., Nazar-Stewart V., Onon-Kihara M., Rannug A., Romkes M., Ryberg D., Seidegard J., Shields P., Strange R. C., Stucker I., To-Figueras J., Brennan P., Taioli E. Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis, 23: 1343-1350, 2002.[Abstract/Free Full Text]
  5. Dirven H. A., Megens L., Oudshoorn M. J., Dingemanse M. A., van Ommen B., Van Bladeren P. J. Glutathione conjugation of the cytostatic drug ifosfamide and the role of human glutathione S-transferases. Chem. Res. Toxicol., 8: 979-986, 1995.[Medline]
  6. Dirven H. A., van Ommen B., Van Bladeren P. J. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res., 54: 6215-6220, 1994.[Abstract/Free Full Text]
  7. Srivastava S. K., Singhal S. S., Hu X., Awasthi Y. C., Zimniak P., Singh S. V. Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch. Biochem. Biophys., 366: 89-94, 1999.[Medline]
  8. Srivastava S. K., Singhal S. S., Guo J., Awasthi S., Zimniak P., Awasthi Y. S., Singh S. V. Activity of polymorphic variants of pi class human glutathione S-transferase toward chlorambucil. Proc. Am. Assoc. Cancer Res., 41: 804 2000.
  9. Goto S., Iida T., Cho S., Oka M., Kohno S., Kondo T. Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radic. Res., 31: 549-558, 1999.[Medline]
  10. Ketterer B. Glutathione S-transferases and prevention of cellular free radical damage. Free Radic. Res., 28: 647-658, 1998.[Medline]
  11. Berhane K., Widersten M., Engstrom A., Kozarich J. W., Mannervik B. Detoxication of base propenals and other alpha, beta-unsaturated aldehyde products of radical reactions and lipid peroxidation by human glutathione transferases. Proc. Natl. Acad. Sci. USA, 91: 1480-1484, 1994.[Abstract/Free Full Text]
  12. Kawajiri K., Eguchi H., Nakachi K., Sekiya T., Yamamoto M. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res., 56: 72-76, 1996.[Abstract/Free Full Text]
  13. Ryberg D., Skaug V., Hewer A., Phillips D. H., Harries L. W., Wolf C. R., Ogreid D., Ulvik A., Vu P., Haugen A. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis, 18: 1285-1289, 1997.[Abstract/Free Full Text]
  14. Matsuzoe D., Hideshima T., Iwasaki A., Yoneda S., Kawahara K., Shirakusa T., Kimura A. Glutathione S-transferase mu1 null genotype is associated with K-ras gene mutation in lung adenocarcinoma among smokers. Carcinogenesis, 22: 1327-1330, 2001.[Abstract/Free Full Text]
  15. Curigliano G., Ferretti G., Mandala M., De Pas T., Calabro M. G., Solli P., Noberasc C., de Braud F. GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis. Anticancer Res., 21: 3461-3469, 2001.[Medline]
  16. Mitsudomi T., Hamajima N., Ogawa M., Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin. Cancer Res., 6: 4055-4063, 2000.[Abstract/Free Full Text]
  17. Goto I., Yoneda S., Yamamoto M., Kawajiri K. Prognostic significance of germ-line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res., 56: 3725-3730, 1996.[Abstract/Free Full Text]
  18. Przygodzki R. M., Bennett W. P., Guinee D. G., Jr., Khan M. A., Freedman A., Shields P. G., Travis W. D., Jett J. R., Tazelaar H., Pairolero P., Trastek V., Liotta L. A., Harris C. C., Caporaso N. E. p53 mutation spectrum in relation to GSTM1, CYP1A1 and CYP2E1 in surgically treated patients with non-small cell lung cancer. Pharmacogenetics, 8: 503-511, 1998.[Medline]
  19. Yang P., Yokomizo A., Tazelaar H. D., Marks R. S., Lesnick T. G., Miller D. L., Sloan J. A., Edell E. S., Meyer R. L., Jett J., Liu W. Genetic determinants of lung cancer short-term survival: the role of glutathione-related genes. Lung Cancer, 35: 221-229, 2002.[Medline]
  20. Ries L. A. G. Eisner M. P. Kosary C. L. Hankey B. F. Miller B. A. Clegg L. Edwards B. K. eds. . SEER Cancer Statistics Review, 1973-1999, National Cancer Institute Bethesda, MD 2002.
  21. Jackson L. A., Wang S. P., Nazar-Stewart V., Grayston J. T., Vaughan T. L. Association of Chlamydia pneumoniae immunoglobulin A seropositivity and risk of lung cancer. Cancer Epidemiol. Biomark. Prev., 9: 1263-1266, 2000.[Abstract/Free Full Text]
  22. Chen C. L., Liu Q., Relling M. V. Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. Pharmacogenetics, 6: 187-191, 1996.[Medline]
  23. Tobe V. O., Taylor S. L., Nickerson D. A. Single-well genotyping of diallelic sequence variations by a two-color ELISA-based oligonucleotide ligation assay. Nucleic Acids Res., 24: 3728-3732, 1996.[Abstract/Free Full Text]
  24. Sweeney C., Farrow D. C., Schwartz S. M., Eaton D. L., Checkoway H., Vaughan T. L. Glutathione S-transferase M1. T1, and P1 polymorphisms as risk factors for renal cell carcinoma: a case-control study. Cancer Epidemiol. Biomark. Prev., 9: 449-454, 2000.[Abstract/Free Full Text]
  25. Ishimoto T. M., Akande O., Ali-Osman F. The different glutathione S-transferase P1 alleles confer to tumor cells a differential resistance to cisplatin through altered GSTP1-catalyzed metabolism of cisplatin. Proc. Am. Assoc. Cancer Res., 43: 321 2002.
  26. Kelsey K. T., Hankinson S. E., Colditz G. A., Springer K., Garcia-Closas M., Spiegelman D., Manson J. E., Garland M., Stampfer M. J., Willett W. C., Speizer F. E., Hunter D. J. Glutathione S-transferase class mu deletion polymorphism and breast cancer: results from prevalent versus incident cases. Cancer Epidemiol. Biomark. Prev., 6: 511-515, 1997.[Abstract]
  27. Ambrosone C. B., Sweeney C., Coles B. F., Thompson P. A., McClure G. Y., Korourian S., Fares M. Y., Stone A., Kadlubar F. F., Hutchins L. F. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res., 61: 7130-7135, 2001.[Abstract/Free Full Text]
  28. Davies S. M., Robison L. L., Buckley J. D., Tjoa T., Woods W. G., Radloff G. A., Ross J. A., Perentesis J. P. Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J. Clin. Oncol., 19: 1279-1287, 2001.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Am J EpidemiolHome page
M. L. Cote, W. Chen, D. W. Smith, S. Benhamou, C. Bouchardy, D. Butkiewicz, K. M. Fong, M. Gene, A. Hirvonen, C. Kiyohara, et al.
Meta- and Pooled Analysis of GSTP1 Polymorphism and Lung Cancer: A HuGE-GSEC Review
Am. J. Epidemiol., April 1, 2009; 169(7): 802 - 814.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
Y.-S. Lin, S.-C. Hung, Y.-H. Wei, and D.-C. Tarng
GST M1 Polymorphism Associates with DNA Oxidative Damage and Mortality among Hemodialysis Patients
J. Am. Soc. Nephrol., February 1, 2009; 20(2): 405 - 415.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
N. Barahmani, S. Carpentieri, X.-N. Li, T. Wang, Y. Cao, L. Howe, L. Kilburn, M. Chintagumpala, C. Lau, and M. F. Okcu
Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma
Neuro-oncol, January 1, 2009; 11(3): 292 - 300.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. G. Schwartz, G. M. Prysak, C. H. Bock, and M. L. Cote
The molecular epidemiology of lung cancer
Carcinogenesis, March 1, 2007; 28(3): 507 - 518.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Oldenburg, S. M. Kraggerud, M. Cvancarova, R. A. Lothe, and S. D. Fossa
Cisplatin-Induced Long-Term Hearing Impairment Is Associated With Specific Glutathione S-Transferase Genotypes in Testicular Cancer Survivors
J. Clin. Oncol., February 20, 2007; 25(6): 708 - 714.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Yang, J. O. Ebbert, Z. Sun, and R. M. Weinshilboum
Role of the Glutathione Metabolic Pathway in Lung Cancer Treatment and Prognosis: A Review
J. Clin. Oncol., April 10, 2006; 24(11): 1761 - 1769.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
H. Sugimura and P. Yang
Long-term Survivorship in Lung Cancer: A Review.
Chest, April 1, 2006; 129(4): 1088 - 1097.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-M. Lee, M.-T. Wu, Y.-C. Lee, S.-Y. Yang, J.-S. Chen, H.-H. Hsu, P.-M. Huang, S.-W. Kuo, C.-J. Lee, and C.-J. Chen
Association of GSTP1 Polymorphism and Survival for Esophageal Cancer
Clin. Cancer Res., July 1, 2005; 11(13): 4749 - 4753.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. R. Spitz, X. Wu, and G. Mills
Integrative Epidemiology: From Risk Assessment to Outcome Prediction
J. Clin. Oncol., January 10, 2005; 23(2): 267 - 275.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sweeney, C.
Right arrow Articles by Vaughan, T. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sweeney, C.
Right arrow Articles by Vaughan, T. L.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online